Medigene AG to report full year 2023 financial results on March 28, 2024
18 mars 2024 10h00 HE
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will...
MetrioPharm stellt wissenschaftlichen Beirat aus erfahrenen Immunologie- und Pädiatrie-Experten vor
13 mars 2024 06h00 HE
|
AKAMPION
Die neuen Beiräte werden ihr Fachwissen in den Bereichen Immunologie, Pathologie, Entzündungsprozesse und in MetrioPharms Hauptindikation Duchenne-Muskeldystrophie einbringenDie Beiräte haben bereits...
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
13 mars 2024 06h00 HE
|
AKAMPION
The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm's lead indication Duchenne muscular dystrophy Advisors have previously collaborated with...
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
06 mars 2024 05h00 HE
|
Medigene AG
Planegg/Martinsried, March 6, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
04 mars 2024 02h00 HE
|
Medigene AG
Planegg/Martinsried, March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid...
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
29 févr. 2024 06h00 HE
|
Medigene AG
Multiple members of management as expert speakers including Prof. Dr. Dolores Schendel, Chief Scientific Officer of Medigene, Dr. Barbara Lösch, Head of Technology & Innovation and Dr. Kirsty...
Medigene to Present at Upcoming Conferences
19 févr. 2024 08h00 HE
|
Medigene AG
Planegg/Martinsried, February 19, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
GeoVax Announces Multiple Patent Issuances and Allowances
13 févr. 2024 09h00 HE
|
GeoVax, Inc.
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
12 févr. 2024 08h00 HE
|
Medigene AG
Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T...
Flow Cytometry in Oncology and Immunology Market Set for Growth Amid Increasing Global Cancer Prevalence
24 janv. 2024 13h24 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Flow Cytometry in Oncology and Immunology Market Report 2023" report has been added to ResearchAndMarkets.com's offering. As per the latest...